ArticleScientific reports2021
Incidence, demographics, and survival of patients with primary pituitary tumors: a SEER database study in 2004-2016.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Excess mortality in radiotherapy-treated pituitary adenoma patients: 50-year follow-up.Journal of the Endocrine Society · 2026Article
- Pituitary Metastasis in Lung Cancer Patients: Case Series and Review of the Literature.Current oncology (Toronto, Ont.) · 2026Review
- Trade-offs in proton and photon radiotherapy for pituitary adenomas.Physics and imaging in radiation oncology · 2026Article
- Surgical outcomes of endoscopic endonasal surgery for nonfunctioning pituitary adenoma in elderly patients: a comprehensive analysis beyond age : Surgery for pituitary adenoma among elderly patients.BMC endocrine disorders · 2026Article
- Associations Between Psoriasis and Endocrine Diagnoses in a Tertiary-Center Electronic Health Record Database: A Cross-Sectional Study.Clinical, cosmetic and investigational dermatology · 2026Article
- Article
- Hospital frailty risk score predicts postoperative outcomes after endoscopic endonasal resection of non-functioning pituitary adenomas.Pituitary · 2025Article
- Comparative mortality in pituitary adenomas subtypes: a tertiary referral center study.Endocrine · 2025Article
- Hormonally Active Pituitary Adenomas and Pregnancy: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2025Review
- Operative considerations for resection of pituitary adenoma in patients with sickle cell disease: A retrospective analysis of 19,653 patients.Surgical neurology international · 2025Article
- Reporting of Participants' Sex, Race, Ethnicity, and Socioeconomic Status in Pituitary Surgery Literature.Journal of neurological surgery. Part B, Skull base · 2024Article
- Associations ofCancers · 2024Article
- Giant Clinically Non-Functioning Pituitary Adenoma Presenting as New Onset Generalized Tonic‒Clonic Seizures: A Case Report.International medical case reports journal · 2024Article
- Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification.Nature reviews. Endocrinology · 2023Review
- Supervised machine learning to validate a novel scoring system for the prediction of disease remission of functional pituitary adenomas following transsphenoidal surgery.Scientific reports · 2023Article
- Recent Therapeutic Advances in Pituitary Carcinoma.Journal of immunotherapy and precision oncology · 2023Review
- A False Pituitary Tumor.JCEM case reports · 2023Article
- Epidemiology of common and uncommon adult pituitary tumors in the U.S. according to the 2017 World Health Organization classification.Pituitary · 2022Article
- The AKT/mTOR Signaling Pathway Was Mediated through the LINC00514/miR-28-5p/TRIM44 Axis.Disease markers · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comprehensive investigations on the incidence and prognosis of pituitary tumors are still lacking. The present study aims to summarize the incidence, demographics, and survival outcome of pituitary adenoma on a population-based level. This study includes all pituitary adenomas reported in the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2016 in the United States. Extensive clinical and demographic characteristics were extracted and submitted to group comparisons. The standardized incidence rate was calculated and stratified by year at diagnosis, age/sex and age/treatment groups. The Kaplan-Meier analysis and multivariable regressions were performed to identify the factors associated with overall survival. A total of 47,180 pituitary tumors were identified, including 47,030 typical adenomas, 111 uncertain behavior pituitary adenomas, and 39 pituitary carcinomas. The overall standardized incidence rate was 4.8 cases per 100,000 person-years and the annual incidence rate continually trended upwards, with a peak seen in 2015. We noticed a bimodal age-related distribution in females and a unimodal distribution in males. In the multivariate regression analysis, the factors associated with prolonged survival included typical adenoma, younger age, and smaller tumor size. Whereas, black and male patients had worse overall survival. Our study provides a reliable estimate on the incidence of pituitary adenoma and confirms that the annual standardized incidence rate is increasing. Pituitary adenomas have a satisfactory long-term prognosis and age, tumor size, and tumor subtypes are related to overall survival. Though statistically significant, our inferential findings should be constrained within the limitations of SEER database.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.